Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,932 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
Balazard F, Bertaut A, Bordet É, Mulard S, Blanc J, Briot N, Paux G, Dhaini Merimeche A, Rigal O, Coutant C, Fournier M, Jouannaud C, Soulie P, Lerebours F, Cottu PH, Tredan O, Vanlemmens L, Levy C, Mouret-Reynier MA, Campone M, Brady KJS, Sasane M, Rice M, Coulouvrat C, Martin AL, Jacquet A, Vaz-Luis I, Herold C, Pistilli B. Balazard F, et al. Among authors: levy c. J Natl Cancer Inst. 2023 Sep 7;115(9):1099-1108. doi: 10.1093/jnci/djad109. J Natl Cancer Inst. 2023. PMID: 37434306 Free PMC article.
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group. Coudert B, et al. Among authors: levy c. Oncologist. 2012;17(7):900-9. doi: 10.1634/theoncologist.2011-0442. Epub 2012 May 18. Oncologist. 2012. PMID: 22610153 Free PMC article. Clinical Trial.
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Pierga JY, Petit T, Lévy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Bonneterre J, Hernandez J, Bidard FC, Viens P. Pierga JY, et al. Among authors: levy c. Clin Cancer Res. 2015 Mar 15;21(6):1298-304. doi: 10.1158/1078-0432.CCR-14-1705. Epub 2014 Dec 23. Clin Cancer Res. 2015. PMID: 25538259 Clinical Trial.
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A. Tabouret E, et al. Among authors: levy c. Oncotarget. 2016 Apr 5;7(14):18531-40. doi: 10.18632/oncotarget.7612. Oncotarget. 2016. PMID: 26921265 Free PMC article. Clinical Trial.
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonneterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY. Bertucci F, et al. Among authors: levy c. Lancet Oncol. 2016 May;17(5):600-11. doi: 10.1016/S1470-2045(16)00011-5. Epub 2016 Mar 28. Lancet Oncol. 2016. PMID: 27032301 Clinical Trial.
Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment.
Lange M, Heutte N, Rigal O, Noal S, Kurtz JE, Lévy C, Allouache D, Rieux C, Lefel J, Clarisse B, Veyret C, Barthélémy P, Longato N, Castel H, Eustache F, Giffard B, Joly F. Lange M, et al. Among authors: levy c. Oncologist. 2016 Nov;21(11):1337-1348. doi: 10.1634/theoncologist.2016-0014. Epub 2016 Jul 29. Oncologist. 2016. PMID: 27473044 Free PMC article.
[Breast cancer screening: On our way to the future].
Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG). Delaloge S, et al. Among authors: levy c. Bull Cancer. 2016 Sep;103(9):753-63. doi: 10.1016/j.bulcan.2016.06.005. Epub 2016 Jul 26. Bull Cancer. 2016. PMID: 27473920 Review. French.
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
Cox DG, Curtit E, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Deleuze JF, Pauporté I, Thomas G, Pivot X. Cox DG, et al. Among authors: levy c. Oncotarget. 2016 Nov 22;7(47):77358-77364. doi: 10.18632/oncotarget.12669. Oncotarget. 2016. PMID: 27764800 Free PMC article.
1,932 results